317 related articles for article (PubMed ID: 29542355)
1. Transcriptional control of the MUC16 promoter facilitates follicle-stimulating hormone peptide-conjugated shRNA nanoparticle-mediated inhibition of ovarian carcinoma in vivo.
Zhang MX; Hong SS; Cai QQ; Zhang M; Chen J; Zhang XY; Xu CJ
Drug Deliv; 2018 Nov; 25(1):797-806. PubMed ID: 29542355
[TBL] [Abstract][Full Text] [Related]
2. Follicle-stimulating hormone peptide-conjugated nanoparticles for targeted shRNA delivery lead to effective gro-α silencing and antitumor activity against ovarian cancer.
Hong SS; Zhang MX; Zhang M; Yu Y; Chen J; Zhang XY; Xu CJ
Drug Deliv; 2018 Nov; 25(1):576-584. PubMed ID: 29461120
[TBL] [Abstract][Full Text] [Related]
3. Targeted paclitaxel nanoparticles modified with follicle-stimulating hormone β 81-95 peptide show effective antitumor activity against ovarian carcinoma.
Zhang X; Chen J; Kang Y; Hong S; Zheng Y; Sun H; Xu C
Int J Pharm; 2013 Sep; 453(2):498-505. PubMed ID: 23811008
[TBL] [Abstract][Full Text] [Related]
4. Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion.
Rao TD; Tian H; Ma X; Yan X; Thapi S; Schultz N; Rosales N; Monette S; Wang A; Hyman DM; Levine DA; Solit D; Spriggs DR
PLoS One; 2015; 10(5):e0126633. PubMed ID: 25965947
[TBL] [Abstract][Full Text] [Related]
5. Follicle-stimulating hormone peptide can facilitate paclitaxel nanoparticles to target ovarian carcinoma in vivo.
Zhang XY; Chen J; Zheng YF; Gao XL; Kang Y; Liu JC; Cheng MJ; Sun H; Xu CJ
Cancer Res; 2009 Aug; 69(16):6506-14. PubMed ID: 19638590
[TBL] [Abstract][Full Text] [Related]
6. Enhanced antitumor effects of follicle-stimulating hormone receptor-mediated hexokinase-2 depletion on ovarian cancer mediated by a shift in glucose metabolism.
Zhang M; Liu Q; Zhang M; Cao C; Liu X; Zhang M; Li G; Xu C; Zhang X
J Nanobiotechnology; 2020 Nov; 18(1):161. PubMed ID: 33160373
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells.
Comamala M; Pinard M; Thériault C; Matte I; Albert A; Boivin M; Beaudin J; Piché A; Rancourt C
Br J Cancer; 2011 Mar; 104(6):989-99. PubMed ID: 21326240
[TBL] [Abstract][Full Text] [Related]
8. Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway.
Matte I; Garde-Granger P; Bessette P; Piché A
BMC Cancer; 2019 Apr; 19(1):406. PubMed ID: 31039761
[TBL] [Abstract][Full Text] [Related]
9. MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis.
Thériault C; Pinard M; Comamala M; Migneault M; Beaudin J; Matte I; Boivin M; Piché A; Rancourt C
Gynecol Oncol; 2011 Jun; 121(3):434-43. PubMed ID: 21421261
[TBL] [Abstract][Full Text] [Related]
10. Retro-inverso follicle-stimulating hormone peptide-mediated polyethylenimine complexes for targeted ovarian cancer gene therapy.
Zhang M; Zhang M; Wang J; Cai Q; Zhao R; Yu Y; Tai H; Zhang X; Xu C
Drug Deliv; 2018 Nov; 25(1):995-1003. PubMed ID: 29667478
[TBL] [Abstract][Full Text] [Related]
11. PPARγ Modulation of Cytokine-Stimulated MUC16 (CA125) Expression in Breast and Ovarian Cancer-Derived Cells.
Morgado M; Carson DD
J Cell Biochem; 2017 Jan; 118(1):163-171. PubMed ID: 27292441
[TBL] [Abstract][Full Text] [Related]
12. Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3.
Garg G; Gibbs J; Belt B; Powell MA; Mutch DG; Goedegebuure P; Collins L; Piwnica-Worms D; Hawkins WG; Spitzer D
BMC Cancer; 2014 Jan; 14():35. PubMed ID: 24447304
[TBL] [Abstract][Full Text] [Related]
13. Membrane-type I matrix metalloproteinase-dependent ectodomain shedding of mucin16/ CA-125 on ovarian cancer cells modulates adhesion and invasion of peritoneal mesothelium.
Bruney L; Conley KC; Moss NM; Liu Y; Stack MS
Biol Chem; 2014 Oct; 395(10):1221-31. PubMed ID: 25205731
[TBL] [Abstract][Full Text] [Related]
14. CA125 (MUC16) gene silencing suppresses growth properties of ovarian and breast cancer cells.
Reinartz S; Failer S; Schuell T; Wagner U
Eur J Cancer; 2012 Jul; 48(10):1558-69. PubMed ID: 21852110
[TBL] [Abstract][Full Text] [Related]
15. Targeted gene silencing using a follicle-stimulating hormone peptide-conjugated nanoparticle system improves its specificity and efficacy in ovarian clear cell carcinoma in vitro.
Hong S; Zhang X; Chen J; Zhou J; Zheng Y; Xu C
J Ovarian Res; 2013 Nov; 6(1):80. PubMed ID: 24252539
[TBL] [Abstract][Full Text] [Related]
16. Tumor-specific expression of shVEGF and suicide gene as a novel strategy for esophageal cancer therapy.
Liu T; Wu HJ; Liang Y; Liang XJ; Huang HC; Zhao YZ; Liao QC; Chen YQ; Leng AM; Yuan WJ; Zhang GY; Peng J; Chen YH
World J Gastroenterol; 2016 Jun; 22(23):5342-52. PubMed ID: 27340350
[TBL] [Abstract][Full Text] [Related]
17. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.
Felder M; Kapur A; Gonzalez-Bosquet J; Horibata S; Heintz J; Albrecht R; Fass L; Kaur J; Hu K; Shojaei H; Whelan RJ; Patankar MS
Mol Cancer; 2014 May; 13():129. PubMed ID: 24886523
[TBL] [Abstract][Full Text] [Related]
18. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.
Gubbels JA; Belisle J; Onda M; Rancourt C; Migneault M; Ho M; Bera TK; Connor J; Sathyanarayana BK; Lee B; Pastan I; Patankar MS
Mol Cancer; 2006 Oct; 5(1):50. PubMed ID: 17067392
[TBL] [Abstract][Full Text] [Related]
19. Development and characterization of carboxy-terminus specific monoclonal antibodies for understanding MUC16 cleavage in human ovarian cancer.
Aithal A; Junker WM; Kshirsagar P; Das S; Kaur S; Orzechowski C; Gautam SK; Jahan R; Sheinin YM; Lakshmanan I; Ponnusamy MP; Batra SK; Jain M
PLoS One; 2018; 13(4):e0193907. PubMed ID: 29708979
[TBL] [Abstract][Full Text] [Related]
20. MUC16 facilitates cervical cancer progression via JAK2/STAT3 phosphorylation-mediated cyclooxygenase-2 expression.
Shen H; Guo M; Wang L; Cui X
Genes Genomics; 2020 Feb; 42(2):127-133. PubMed ID: 31736008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]